Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the period from January 23, 2026, to March 20, 2026, with the report issued on March 23, 2026. The filing serves as a notification to the market regarding the admission of additional ordinary shares to trading on the London Stock Exchange Main Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding share admissions and does not contain financial performance data.
Material Changes
The material change reported is the admission of 96,525 additional Ordinary Shares of 31½ pence each to trading. These shares are connected to the "GlaxoSmithKline plc Share Save Plan 2012 and 2022." Following this admission, the total number of securities admitted to trading stands at 4,316,176,278.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document strictly addresses the procedural admission of shares under PRM 1.6.4R.
Investor Verification Checklist
- Verify the total number of outstanding shares (4,316,176,278) against the company's latest annual report.
- Confirm the ISIN code (GB00BN7SWP63) for the Ordinary Shares of 31½ pence each.
- Review the terms of the "GlaxoSmithKline plc Share Save Plan 2012 and 2022" to understand the source of the new shares.
- Note that this filing does not impact the company's financial statements or operational metrics.